<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01058252</url>
  </required_header>
  <id_info>
    <org_study_id>GIVF-1001</org_study_id>
    <nct_id>NCT01058252</nct_id>
  </id_info>
  <brief_title>Minimal Stimulation Protocol Using Aromek(Letrozole) and Follitrope(recFSH) Combined With INVOCell-Low Cost IVF</brief_title>
  <acronym>MSP-IVC</acronym>
  <official_title>A Scientific &amp; Clinical Review of Minimal Stimulation Protocol Using AROMEK (Letrozole) and Follitrope (Recombinant FSH)Combined With INVOCell(Intravaginal Culturing) - Effectiveness as Low Cost IVF</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galaxy Pharma (Pvt) Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Galaxy IVF</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AMERICAN IVF &amp; PREGNANCY CENTRE - KARACHI</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fertility Care Multan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>FRIENDS IVF, Faisalabad</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Galaxy Pharma (Pvt) Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study to evaluate a low cost minimal stimulation protocol combined with
      Intravaginal Culturing, to make IVF affordable and available across the large
      infertile/subfertile population
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In routine ART procedures for IVF, ovarian stimulation is performed using down regulation
      with GNRH Agonist combined with high daily FSH doses followed with ovulation induction with
      HCG 10000 IU, ovum pick-up 34-36 hours after HCG injection and embryo transfer on day 2, 3 or
      5.

      In routine ART procedure for IVF, embryology is done in very high tech lab, contamination
      free environment, which also exclude VOC, high quality CO2 Incubators, laminar flow with
      heated table top, high magnification stereo microscope along with equipments for maintaining
      quality control, with a highly trained embryologist. The primary reason is we need to create
      a womb like environment in the embryology lab as eggs, and mainly fertilised embryos are
      going to spend minimum 2 or 3 and in case blastocyst 5 days in this lab.

      In recent years, various studies have been published identifying various minimal stimulation
      protocols for IVF, and also another variation of IVF where rather than using CO2 Incubator
      for culturing, vaginal cavity of the female partner is used for incubation using a specially
      designed capsule which have walls permeable to vaginal pCO2 and O2. Oocytes are retrieved by
      the physician and handed over to basic embryologist to identify and grade oocytes and washed
      sperms are placed in a embryo toxic tested, sterile, individual single use capsule (INVOCell)
      and placed in vaginal cavity using diaphragm, patient goes back to home with some
      instructions for care, on day 2 patient comes back to the IVF Clinic and physician gets the
      capsule out and hands over to the basic embryologist trained on INVOCell to identify embryos
      and grade them, further loading of embryos on ET Catheter.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2011</start_date>
  <completion_date type="Anticipated">February 2012</completion_date>
  <primary_completion_date type="Anticipated">December 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Follicles &gt;15 mm on the day of HCG; Number of Oocytes aspirated; Fertilisation Rate</measure>
    <time_frame>Quarterly</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pregnancy Rate; Cost of Treatment</measure>
    <time_frame>Every 6 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Primary Infertility</condition>
  <condition>Secondary Infertility</condition>
  <condition>Low Responders</condition>
  <condition>Mild to Moderate Male Factor Infertility</condition>
  <arm_group>
    <arm_group_label>Letrozole, recFSH, IVC, Monitoring</arm_group_label>
    <description>Infertile couple following MSP with IVC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole 2.5 mg, recFSH 75 IU</intervention_name>
    <description>OVARIAN STIMULATION:
In previous cycles, cycle length and ovulatory status must be assessed and documented.
STEP 1: ANOVULATION by ORAL CONTRACEPTION
Place patients on monophasic low dose of oral contraceptive pills (OCP) such as Marvelon (Organon, 0.03 mg) continuously for 21 days, 22 days but no more.
Before stopping the oral contraceptive pills, perform an ultrasound to check for the absence of cysts (no cyst &gt; 10 mm).
Give estradiol (2mg, 3 times a day) for 3 days from D21 or D22 and wait for bleeding.
STEP 2: STIMULATION and MONITORING Day one of the cycle equals the first day of bleeding (not spotting).
On Day 3 (D3), start letrozol 2.5mg (AROMEK) for 5 days (D7). LetrozolE can be pushed for 2 more days.
Start hMG or FSH (75 IU a day) on Day 3 like LetrozolE and continue for 5 to 7 days without increasing the dose. The dose of hMG OR FSH can be increased to 150 IU a day if low responder.</description>
    <arm_group_label>Letrozole, recFSH, IVC, Monitoring</arm_group_label>
    <other_name>Aromek (Letrozole 2.5 mg);</other_name>
    <other_name>Follitrope (Recombinent FSH - 75 IU)</other_name>
    <other_name>IVF-C 5000 IU (HCG)</other_name>
    <other_name>Ova-Surge (Urinary LH Surge Kit)</other_name>
    <other_name>Indomethacin 50 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>STEP-3: LH Suppression &amp; Monitoring</intervention_name>
    <description>Baseline Day-2 Ultrasound to estimate antral follicles; Follow-up TVS scans on Day- 5,6,7,8 and 9 of the stimulated cycle. Ideally the lead follicle should be 18 mm on or around day 10 of the cycle.
â€¢ When the leading follicle reaches 14 to15 mm (D8 or D9), give Indomethacine (50 mg, 3 times a day) until the evening preceding the egg retrieval. The Indomethacine will prevent a premature ovulation.
The endometrium should be minimum 8 mm on the day of HCG (IVF-C 5000 IU x 2)
No need of LH testing, or E2 testsing during the stimulated cycle.</description>
    <arm_group_label>Letrozole, recFSH, IVC, Monitoring</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>STEP-4: HCG Timing</intervention_name>
    <description>IVF-C (HCG 10000 IU) shall be injected to trigger the ovulation, when any of the following occur:
E2 level is over 150 pg/ml/per mature follicle (&gt; 15 mm)
Domminent follicle is greater than 18 mm in mean diameter
LH Remains as Baseline, OR
The day when Urinary LH Surge is positive</description>
    <arm_group_label>Letrozole, recFSH, IVC, Monitoring</arm_group_label>
    <other_name>IVF-C 5000 IU</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>STEP-5: OPU, ET, Cancellation</intervention_name>
    <description>Ultrasound guided Ovum Pick-Up is performed 34-36 hours after IVF-C (HCG 10000 IU) injection.
Embryo Transfer is performed after 48-72 hours of incubation at 4-8 cell stage.
Maximum of 2 embryos are transferred, using ultrasound guided transfer.
Cancellation Criteria:
Poor patient compliance
Premature Ovulation
Premature LH Surge
Endometrium &lt; 7 mm
Poor Follicular Development
E2 Level &gt; 2,500 pg/ml</description>
    <arm_group_label>Letrozole, recFSH, IVC, Monitoring</arm_group_label>
    <other_name>Ovum Pick-Up</other_name>
    <other_name>Embryo Transfer</other_name>
    <other_name>Ultrasound Guided</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>INVOCell (Intravaginal Culturing)</intervention_name>
    <description>Sperm preparation through Swim-Up or Gradient is performed 1 hour prior to the oocyte retrieval; Fill the device without air bubble. Only 30000 motile spermatozoa are added into the device; After follicle aspiration, oocyte(s) are identified in the follicular fluid and immediately placed into the device; The device is closed, placed into a protective outer rigid shell and then positioned into the vaginal cavity for 2 to 3 days; No activity restriction is required for the patient, except baths. After 2 or 3 days of incubation, the retention system and the device are removed from the vagina in sterile environment. The device is opened and the contents are observed in a sterile environment under microscope to find the embryos. The two best quality embryos are loaded into embryo transfer catheter and transferred immediately unto the uterine cavity using aseptic techniques.</description>
    <arm_group_label>Letrozole, recFSH, IVC, Monitoring</arm_group_label>
    <other_name>INVOCell</other_name>
    <other_name>Diaphragm (Retention Device)</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        IVF Network Centers across the country, selecting patients meeting inclusion criteria.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Tubal factor without Hydrosalpinx

          -  Unexplained infertility with unsuccessful attempts in achieving pregnancy through
             timed intercourse or IUI

          -  Boarder line male factor infertility

          -  Sperm DNA Fragmentation &lt; 30%

          -  Normal Uterine Cavity

          -  Normal baseline ultrasound with adequate number of primary follicles present

          -  Normal FSH and E2 on Day 3

          -  Age of the female is &lt; 35 years old

        Exclusion Criteria:

          -  If previous IVF or INVO attempts resulted in failed fertilisation

          -  Male partner who has difficulty in producing semen sample

          -  Very low sperm count, very low percentage of sperm motility and morphology

          -  Sperm DNA Fragmentation &gt; 30%

          -  Age of female patient &gt; 37 years

          -  Borderline or elevated E2 or FSH on day 3 or failed CCCT or low blood inhibin levels

          -  Poor ovarian response

          -  Hydrosalpinx

          -  Anatomic difficulties in reaching ovaries for oocyte retrieval

          -  Cervical stenosis, making embryo transfer difficult

          -  Uterine abnormalities or deformities

          -  Obesity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>37 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof. Claude Ranoux, MD</last_name>
    <role>Study Chair</role>
    <affiliation>INVOBioscience, USA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Prof. Claude Ranoux, MD</last_name>
    <phone>978 878-9505</phone>
    <email>clauderanoux@invobioscience.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Saif Ur Rehman</last_name>
    <phone>0092 323 2440710</phone>
    <email>saifrehman@galaxyivf.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Friends Ivf</name>
      <address>
        <city>Faisalabad</city>
        <state>Punjab</state>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Samina Khalid, MCPS, FCPS</last_name>
      <phone>0092 300 8664227</phone>
    </contact>
    <investigator>
      <last_name>Dr. Samina Khalid, MCPS, FCPS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fertility Care Multan</name>
      <address>
        <city>Multan</city>
        <state>Punjab</state>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prof. Samee Akhtar</last_name>
      <phone>0092 300 8637070</phone>
    </contact>
    <investigator>
      <last_name>Prof. Samee Akhtar, FCPS, FRCOG</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Talha Mabood Paracha, Embryologyst</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Galaxy IVF Limited</name>
      <address>
        <city>Karachi</city>
        <state>Sindh</state>
        <zip>75300</zip>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saif Ur Rehman</last_name>
      <phone>0092 323 2440710</phone>
      <email>saifrehman@galaxyivf.com</email>
    </contact>
    <contact_backup>
      <last_name>Talha Mabood Paracha, Embryologyst</last_name>
    </contact_backup>
    <investigator>
      <last_name>Talha Mabood Paracha, Embryologyst</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>American IVF &amp; Pregnancy Center</name>
      <address>
        <city>Karachi</city>
        <state>Sindh</state>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Asma Munir, MCPS, FCPS</last_name>
    </contact>
    <contact_backup>
      <last_name>Pervaiz Masood Khan</last_name>
    </contact_backup>
    <investigator>
      <last_name>Prof. Claude Ranoux, MS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <reference>
    <citation>Hewitt J. Intravaginal culture: present and potential uses. Br J Hosp Med. 1990 Sep;44(3):182, 184-5, 188. Review.</citation>
    <PMID>2257400</PMID>
  </reference>
  <results_reference>
    <citation>Ranoux C, Poirot C, Foulot H, Aubriot FX, Dubuisson JB, Chevallier O. [Intravaginal culture and embryo transfer]. Rev Fr Gynecol Obstet. 1988 Oct;83(10):637-8. French.</citation>
    <PMID>3201055</PMID>
  </results_reference>
  <results_reference>
    <citation>Ranoux C, Aubriot FX, Dubuisson JB, Cardone V, Foulot H, Poirot C, Chevallier O. A new in vitro fertilization technique: intravaginal culture. Fertil Steril. 1988 Apr;49(4):654-7.</citation>
    <PMID>3350160</PMID>
  </results_reference>
  <results_reference>
    <citation>Sterzik K, Rosenbusch B, Sasse V, Wolf A, Beier HM, Lauritzen C. A new variation of in-vitro fertilization: intravaginal culture of human oocytes and cleavage stages. Hum Reprod. 1989 Nov;4(8 Suppl):83-6.</citation>
    <PMID>2613877</PMID>
  </results_reference>
  <results_reference>
    <citation>Freude G, Artner B, Leodolter S. [Intravaginal culture--simplification of IVF]. Wien Med Wochenschr. 1990 Oct 31;140(20):498-501. German.</citation>
    <PMID>2264352</PMID>
  </results_reference>
  <results_reference>
    <citation>Sterzik K, Rosenbusch B, Sasse V, Terinde R, Wolf A, Beier HM, Lauritzen C. [Experiences and successes with intravaginal fertilization and culture of human oocytes]. Geburtshilfe Frauenheilkd. 1988 Dec;48(12):850-3. German.</citation>
    <PMID>3234716</PMID>
  </results_reference>
  <results_reference>
    <citation>Sh Tehrani Nejad E, Abediasl Z, Rashidi BH, Azimi Nekoo E, Shariat M, Amirchaghmaghi E. Comparison of the efficacy of the aromatase inhibitor letrozole and clomiphen citrate gonadotropins in controlled ovarian hyperstimulation: a prospective, simply randomized, clinical trial. J Assist Reprod Genet. 2008 May;25(5):187-90. doi: 10.1007/s10815-008-9209-2. Epub 2008 Apr 19.</citation>
    <PMID>18427974</PMID>
  </results_reference>
  <results_reference>
    <citation>Grabia A, Papier S, Pesce R, Mlayes L, Kopelman S, Sueldo C. Preliminary experience with a low-cost stimulation protocol that includes letrozole and human menopausal gonadotropins in normal responders for assisted reproductive technologies. Fertil Steril. 2006 Oct;86(4):1026-8. Epub 2006 Aug 28.</citation>
    <PMID>16935285</PMID>
  </results_reference>
  <results_reference>
    <citation>Baysoy A, Serdaroglu H, Jamal H, Karatekeli E, Ozornek H, Attar E. Letrozole versus human menopausal gonadotrophin in women undergoing intrauterine insemination. Reprod Biomed Online. 2006 Aug;13(2):208-12.</citation>
    <PMID>16895634</PMID>
  </results_reference>
  <results_reference>
    <citation>Jee BC, Ku SY, Suh CS, Kim KC, Lee WD, Kim SH. Use of letrozole versus clomiphene citrate combined with gonadotropins in intrauterine insemination cycles: a pilot study. Fertil Steril. 2006 Jun;85(6):1774-7. Epub 2006 May 4.</citation>
    <PMID>16677640</PMID>
  </results_reference>
  <results_reference>
    <citation>Garcia-Velasco JA, Moreno L, Pacheco A, GuillÃ©n A, Duque L, Requena A, Pellicer A. The aromatase inhibitor letrozole increases the concentration of intraovarian androgens and improves in vitro fertilization outcome in low responder patients: a pilot study. Fertil Steril. 2005 Jul;84(1):82-7.</citation>
    <PMID>16009161</PMID>
  </results_reference>
  <results_reference>
    <citation>Verpoest WM, Kolibianakis E, Papanikolaou E, Smitz J, Van Steirteghem A, Devroey P. Aromatase inhibitors in ovarian stimulation for IVF/ICSI: a pilot study. Reprod Biomed Online. 2006 Aug;13(2):166-72.</citation>
    <PMID>16895628</PMID>
  </results_reference>
  <results_reference>
    <citation>Ozmen B, SÃ¶nmezer M, Atabekoglu CS, Olmus H. Use of aromatase inhibitors in poor-responder patients receiving GnRH antagonist protocols. Reprod Biomed Online. 2009 Oct;19(4):478-85.</citation>
    <PMID>19909587</PMID>
  </results_reference>
  <results_reference>
    <citation>Goswami SK, Das T, Chattopadhyay R, Sawhney V, Kumar J, Chaudhury K, Chakravarty BN, Kabir SN. A randomized single-blind controlled trial of letrozole as a low-cost IVF protocol in women with poor ovarian response: a preliminary report. Hum Reprod. 2004 Sep;19(9):2031-5. Epub 2004 Jun 24.</citation>
    <PMID>15217999</PMID>
  </results_reference>
  <results_reference>
    <citation>Kadoch IJ, Al-Khaduri M, Phillips SJ, LapensÃ©e L, Couturier B, Hemmings R, Bissonnette F. Spontaneous ovulation rate before oocyte retrieval in modified natural cycle IVF with and without indomethacin. Reprod Biomed Online. 2008 Feb;16(2):245-9.</citation>
    <PMID>18284881</PMID>
  </results_reference>
  <results_reference>
    <citation>Janssens RM, Lambalk CB, Vermeiden JP, Schats R, Schoemaker J. In-vitro fertilization in a spontaneous cycle: easy, cheap and realistic. Hum Reprod. 2000 Feb;15(2):314-8.</citation>
    <PMID>10655301</PMID>
  </results_reference>
  <results_reference>
    <citation>Bernabeu R, Roca M, Torres A, Ten J. Indomethacin effect on implantation rates in oocyte recipients. Hum Reprod. 2006 Feb;21(2):364-9. Epub 2005 Nov 10.</citation>
    <PMID>16284067</PMID>
  </results_reference>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 27, 2010</study_first_submitted>
  <study_first_submitted_qc>January 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2010</study_first_posted>
  <last_update_submitted>February 6, 2011</last_update_submitted>
  <last_update_submitted_qc>February 6, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 8, 2011</last_update_posted>
  <responsible_party>
    <name_title>Saif Ur Rehman, Project Director</name_title>
    <organization>Galaxy IVF (UK) Limited</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

